Edition:
United Kingdom

Alder Says Eptinezumab Met Primary Endpoint In Pivotal Phase 3 Promise 2 Clinical Trial


Monday, 8 Jan 2018 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER ANNOUNCES EPTINEZUMAB SIGNIFICANTLY REDUCES MIGRAINE RISK MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PIVOTAL PROMISE 2 PHASE 3 TRIAL FOR CHRONIC MIGRAINE PREVENTION.ALDER BIOPHARMACEUTICALS INC - ANNOUNCED THAT EPTINEZUMAB, MET PRIMARY ENDPOINT IN ITS PIVOTAL PHASE 3 PROMISE 2 CLINICAL TRIAL.ALDER BIOPHARMACEUTICALS INC - ‍15% OF PATIENTS HAD NO MIGRAINES FOR A FULL THREE MONTHS​.ALDER BIOPHARMACEUTICALS INC - IN ADDITION, EPTINEZUMAB MET ALL KEY SECONDARY ENDPOINTS WITH VERY HIGH STATISTICAL SIGNIFICANCE.ALDER BIOPHARMACEUTICALS INC - ‍SAFETY AND TOLERABILITY WERE SIMILAR TO PREVIOUSLY REPORTED EPTINEZUMAB STUDIES​.ALDER BIOPHARMACEUTICALS INC - PLANS TO SUBMIT A BLA TO U.S. FDA FOR EPTINEZUMAB IN H2 OF 2018. 

Company Quote

11.06
0.05 +0.45%
24 May 2019